Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel.

Leithäuser B, Zielske D, Seyfert UT, Jung F

Clinical hemorheology and microcirculation1 Jan 2008Cited by 33 (Europe PMC)

PMID18503138DOI10.3233/ch-2008-1092PepBankPUB-18503138

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialActivity measurement
In volunteers receiving clopidogrel, desmopressin increased ristocetin cofactor by 31.9% (p=0.0329).
In plain wordsIn volunteers receiving clopidogrel, desmopressin increased ristocetin cofactor by 31.9% compared with before treatment.
Peptide
Desmopressin
Outcome
IncreaseRistocetin cofactor
Study
n = 9
Comparator
Before desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
300 mug · nasalAs given in this study (human).
Measurements
Ristocetin cofactor increase
31.9%
Desmopressin 300 mug nasal after clopidogrel, n=9; change after dosing
Source sentences
Summary
Ristocetin cofactor and platelet reactivity rose significantly after the administration of Octostim nasal spray with 31.9% and 5.3%, respectively (p=0.0329; p=0.0414).
2 context sentences(design, population, supporting numbers)
Summary · context
The trial was conducted as an open, prospective, single-centre, randomised pilot study with n=17 healthy volunteers in a parallel-group design.
Summary · context
1 h after an oral loading dose of 375 mg clopidogrel the effects of a single-dose of 300 mug of Octostim nasal spray (n=9) on platelet aggregation, activity of platelets on the density of membrane-bound receptors are measured.
Report a problemFND-1850313801
02HumanNon-randomized trialActivity measurement
In volunteers receiving clopidogrel, desmopressin increased platelet reactivity by 5.3% (p=0.0414).
In plain wordsIn volunteers receiving clopidogrel, desmopressin increased platelet reactivity by 5.3% compared with before treatment.
Peptide
Desmopressin
Outcome
IncreasePlatelet reactivity
Study
n = 9
Comparator
Before desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
300 mug · nasalAs given in this study (human).
Measurements
Platelet reactivity increase
5.3%
Desmopressin 300 mug nasal after clopidogrel, n=9; change after dosing
Source sentences
Summary
Ristocetin cofactor and platelet reactivity rose significantly after the administration of Octostim nasal spray with 31.9% and 5.3%, respectively (p=0.0329; p=0.0414).
2 context sentences(design, population, supporting numbers)
Summary · context
The trial was conducted as an open, prospective, single-centre, randomised pilot study with n=17 healthy volunteers in a parallel-group design.
Summary · context
1 h after an oral loading dose of 375 mg clopidogrel the effects of a single-dose of 300 mug of Octostim nasal spray (n=9) on platelet aggregation, activity of platelets on the density of membrane-bound receptors are measured.
Report a problemFND-1850313802
03HumanNon-randomized trialActivity measurement
In volunteers receiving clopidogrel, ADP-induced aggregation increased approximately 20% after desmopressin, without significance (p=0.0564).
In plain wordsIn volunteers receiving clopidogrel, platelet aggregation increased approximately 20% after desmopressin, without a significant difference.
Peptide
Desmopressin
Outcome
No significant changeADP-induced platelet aggregation
Study
n = 9
Comparator
Before desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
300 mug · nasalAs given in this study (human).
Measurements
ADP-induced platelet aggregation increase
≈ 20%
Desmopressin 300 mug nasal after clopidogrel, n=9; change after dosing
Source sentences
Summary
The ADP-induced platelet aggregation increased after the administration of Octostim nasal spray by approximately 20% (p=0.0564).
2 context sentences(design, population, supporting numbers)
Summary · context
The trial was conducted as an open, prospective, single-centre, randomised pilot study with n=17 healthy volunteers in a parallel-group design.
Summary · context
1 h after an oral loading dose of 375 mg clopidogrel the effects of a single-dose of 300 mug of Octostim nasal spray (n=9) on platelet aggregation, activity of platelets on the density of membrane-bound receptors are measured.
Report a problemFND-1850313803
04HumanNon-randomized trialActivity measurement
In volunteers receiving clopidogrel, CD62-positive platelets did not change after desmopressin (p=0.4203).
In plain wordsIn volunteers receiving clopidogrel, desmopressin did not change the fraction of CD62-positive platelets.
Peptide
Desmopressin
Outcome
No significant changeCD62-positive platelets
Study
n = 9
Comparator
Before desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
300 mug · nasalAs given in this study (human).
Source sentences
Summary
The fraction of CD62- and CD63-positive platelets did not change after clopidogrel nor after desmopressin (p=0.4203; p=0.6774).
2 context sentences(design, population, supporting numbers)
Summary · context
The trial was conducted as an open, prospective, single-centre, randomised pilot study with n=17 healthy volunteers in a parallel-group design.
Summary · context
1 h after an oral loading dose of 375 mg clopidogrel the effects of a single-dose of 300 mug of Octostim nasal spray (n=9) on platelet aggregation, activity of platelets on the density of membrane-bound receptors are measured.
Report a problemFND-1850313804
05HumanNon-randomized trialActivity measurement
In volunteers receiving clopidogrel, CD63-positive platelets did not change after desmopressin (p=0.6774).
In plain wordsIn volunteers receiving clopidogrel, desmopressin did not change the fraction of CD63-positive platelets.
Peptide
Desmopressin
Outcome
No significant changeCD63-positive platelets
Study
n = 9
Comparator
Before desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
300 mug · nasalAs given in this study (human).
Source sentences
Summary
The fraction of CD62- and CD63-positive platelets did not change after clopidogrel nor after desmopressin (p=0.4203; p=0.6774).
2 context sentences(design, population, supporting numbers)
Summary · context
The trial was conducted as an open, prospective, single-centre, randomised pilot study with n=17 healthy volunteers in a parallel-group design.
Summary · context
1 h after an oral loading dose of 375 mg clopidogrel the effects of a single-dose of 300 mug of Octostim nasal spray (n=9) on platelet aggregation, activity of platelets on the density of membrane-bound receptors are measured.
Report a problemFND-1850313805
06HumanNon-randomized trialActivity measurement
In volunteers receiving clopidogrel, GPIIb/IIIa receptor density did not change after desmopressin (p=0.9652).
In plain wordsIn volunteers receiving clopidogrel, desmopressin did not change GPIIb/IIIa receptor density.
Peptide
Desmopressin
Outcome
No significant changeGPIIb/IIIa receptor density
Study
n = 9
Comparator
Before desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
300 mug · nasalAs given in this study (human).
Source sentences
Summary
The density of GPIIb/IIIa receptors per platelet did not change after desmopressin (p=0.9652).
2 context sentences(design, population, supporting numbers)
Summary · context
The trial was conducted as an open, prospective, single-centre, randomised pilot study with n=17 healthy volunteers in a parallel-group design.
Summary · context
1 h after an oral loading dose of 375 mg clopidogrel the effects of a single-dose of 300 mug of Octostim nasal spray (n=9) on platelet aggregation, activity of platelets on the density of membrane-bound receptors are measured.
Report a problemFND-1850313806
07HumanNon-randomized trialActivity measurement
In volunteers receiving clopidogrel, GPIb/IX receptor density rose after desmopressin without reaching significance (p=0.0802), and by 5.5% in the desmopressin group alone (p=0.0783).
In plain wordsIn volunteers receiving clopidogrel, receptor density rose 5.5% after desmopressin, without a significant difference.
Peptide
Desmopressin
Outcome
No significant changeGPIb/IX receptor density
Study
n = 9
Comparator
Before desmopressin
Outcome group
Bleeding and clotting · Whole body
Studied dose
300 mug · nasalAs given in this study (human).
Measurements
GPIb/IX receptor density increase
5.5%
Desmopressin group alone, n=9
Source sentences
Summary
In the desmopressin group alone the receptor density rose by 5.5% (p=0.0783).
3 context sentences(design, population, supporting numbers)
Summary · context
The density of GPIb/IX receptors per platelet rose after desmopressin without reaching the level of significance (p=0.0802).
Summary · context
The trial was conducted as an open, prospective, single-centre, randomised pilot study with n=17 healthy volunteers in a parallel-group design.
Summary · context
1 h after an oral loading dose of 375 mg clopidogrel the effects of a single-dose of 300 mug of Octostim nasal spray (n=9) on platelet aggregation, activity of platelets on the density of membrane-bound receptors are measured.
Report a problemFND-1850313807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.